Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Antiviral Res. 2016 May 15;132:13–25. doi: 10.1016/j.antiviral.2016.05.009

Figure 8.

Figure 8

peg-ArgI inhibits replication of HSV-2. Vero cells treated with either peg-ArgI (5µg/ml) or acyclovir (50µM) were infected with HSV-2(G) at a multiplicity of infection (MOI) of 0.1, 1.0 or 5.0. The total HSV-2 infectious viral yield was determined at 24h post-infection by titering lysed cell stocks on Vero cells. Each bar represents the mean +/− the S.E.M. of three replicates. Experiments were repeated at least 3 times. One way analysis of variance (ANOVA) with Kruskal-Wallis post-test was utilized to analyze differences between all treatment groups at a given MOI. Asterisks indicate significant differences between the indicated treatments: *** p<0.0001. The limit of detection for these assays was 50 plaque forming units/ml.